MICB and plasma cell myeloma: Other groups demonstrated that high concentrations of the Hsp90 inhibitor 17-AAG (1 and 6 μM) up-regulate the cell surface density of MICA and MICB on multiple myeloma cells and Hodgkin’s lymphoma cells and thereby can enhance NK cell cytotoxicity [6, 7].